Risankizumab Intravenous Infusion for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Consider premedication (antihistamine and/or paracetamol) if infusion-related reactions are anticipated ^{(ref 1)}
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded
Confirm patient does not have a history of current or recent infection, or recent exposure to chicken pox or TB
Immunisations
- Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines
- If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab
- Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment

Skyrizi 600 mg per 10mL vial

Already in solution

Dilute further prior to administration

Sodium chloride 0.9% or Glucose 5%

Intermittent intravenous infusion (using an electronically controlled infusion device)

This is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate personal protective equipment. ^{(ref 1)}
Prepare and administer according to the following table

Indication	Intravenous induction dose	Number of 600mg/10mL vials	Volume of infusion fluid	Infusion duration
Crohn's disease	600mg	1	100, 250 or 500mL	at least 60 minutes
Ulcerative colitis	1200mg	2	250 or 500mL	at least 120 minutes
Do not shake the solution in the vial or in the infusion bag

Crohn's disease

Give 600mg at week 0,4 and 8
Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

Ulcerative colitis

Give 1200mg at week 0,4 and 8
Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

Renal or hepatic impairment

Store between 2 and 8⁰C

SPC July 2024

1: Injectable medicines guide, Medusa, Downloaded Oct 2024

Immunosuppressant, interleukin inhibitor